GlassScriptPhysician profile
Stacey Sproull
NPI 1528412624
$2,717.05
in general payments reported to CMS, 2019-2025
35 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,034 · 2022: $122 · 2023: $540 · 2024: $774 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.77 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $404.60 | 2021-2024 | Tecvayli, Darzalex, Imbruvica |
| Seagen INC. | $305.43 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $247.42 | 2021-2025 | |
| Genmab U.S., INC. | $155.77 | 2024 | Epkinly |
| G1 Therapeutics, INC. | $146.19 | 2023 | Cosela |
| Foundation Medicine, INC. | $134.16 | 2021 | |
| Incyte Corporation | $111.50 | 2021-2023 | Jakafi |
| Myriad Genetic Laboratories, INC. | $109.52 | 2021 | |
| Kite Pharma, INC. | $91.91 | 2025 | Yescarta |
| Glaxosmithkline, LLC. | $77.56 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Daiichi Sankyo INC. | $71.57 | 2021-2023 | Enhertu |
| Lilly USA, LLC | $64.51 | 2021-2023 | Jaypirca, Verzenio |
| Gilead Sciences, INC. | $58.29 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $58.18 | 2021-2024 | Ultomiris |
| Abbvie INC. | $56.71 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $55.97 | 2023-2024 | Calquence, Enhertu |
| Pfizer INC. | $55.85 | 2021-2024 | |
| Amgen INC. | $54.56 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $52.54 | 2023-2024 | Onivyde, Somatuline Depot |
| Taiho Oncology, INC. | $41.91 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.31 | 2021 | |
| Puma Biotechnology, INC. | $40.65 | 2024-2025 | |
| Dova Pharmaceuticals | $35.49 | 2021 | |
| Exelixis INC. | $33.33 | 2022 | |
| Genentech USA, INC. | $27.58 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.71 | 2023 | Alunbrig |
| Genzyme Corporation | $23.13 | 2022 | |
| Sobi, INC | $21.56 | 2023 | |
| Eisai INC. | $20.64 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $19.51 | 2024 | Libtayo |
| Celgene Corporation | $16.87 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.73 | 2024 | |
| Jazz Pharmaceuticals INC. | $14.28 | 2023 | |
| Deciphera Pharmaceuticals INC. | $13.98 | 2021 | |
| Merck Sharp & Dohme LLC | $13.13 | 2023 | Keytruda, Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Sproull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.